{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:04:58Z","timestamp":1791223498288,"version":"4.1.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Basic to Translational Science"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jacbts.2025.04.011","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T18:41:24Z","timestamp":1754505684000},"page":"101297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Hydrogen Sulfide Deficiency and Therapeutic Targeting in Cardiometabolic HFpEF"],"prefix":"10.1016","volume":"10","author":[{"given":"Jake E.","family":"Doiron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2437-1773","authenticated-orcid":false,"given":"Mahmoud H.","family":"Elbatreek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijing","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoman","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie D.","family":"Gehred","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Gromova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingshu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian H.","family":"Driver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Muraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smitha","family":"Shambhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8335-735X","authenticated-orcid":false,"given":"W.H. Wilson","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle B.","family":"LaPenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Thomas E.","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traci T.","family":"Goodchild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Xian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Quiriarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6364-5787","authenticated-orcid":false,"given":"Timothy D.","family":"Allerton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Zagouras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5655-8201","authenticated-orcid":false,"given":"Sanjiv J.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Pfeilschifter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Friedrich","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5238-1245","authenticated-orcid":false,"given":"Thomas M.","family":"Vondriska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Lefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacbts.2025.04.011_bib1","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacbts.2025.04.011_bib2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.amjcard.2016.04.015","article-title":"Comparison of length of stay, 30-day mortality, and 30-day readmission rates in Medicare patients with heart failure and with reduced versus preserved ejection fraction","volume":"118","author":"Loop","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacbts.2025.04.011_bib3","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1161\/CIRCRESAHA.119.313572","article-title":"Heart failure with preserved ejection fraction in perspective","volume":"124","author":"Pfeffer","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.jacbts.2025.04.011_bib4","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1161\/CIRCULATIONAHA.119.041886","article-title":"Research priorities for heart failure with preserved ejection fraction","volume":"141","author":"Shah","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2025.04.011_bib5","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41586-019-1100-z","article-title":"Nitrosative stress drives heart failure with preserved ejection fraction","volume":"568","author":"Schiattarella","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jacbts.2025.04.011_bib6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jacbts.2017.05.004","article-title":"Nitric Oxide Signaling in heart failure with preserved ejection fraction","volume":"2","author":"Cruz","year":"2017","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jacbts.2025.04.011_bib7","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3389\/fphar.2017.00686","article-title":"The role of hydrogen sulfide on cardiovascular homeostasis: an overview with update on immunomodulation","volume":"8","author":"Pan","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jacbts.2025.04.011_bib8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41569-022-00741-6","article-title":"Sulfide regulation of cardiovascular function in health and disease","volume":"20","author":"Kolluru","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacbts.2025.04.011_bib9","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1093\/emboj\/20.21.6008","article-title":"The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener","volume":"20","author":"Zhao","year":"2001","journal-title":"EMBO J"},{"key":"10.1016\/j.jacbts.2025.04.011_bib10","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1126\/science.1162667","article-title":"H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine \u03b3-lyase","volume":"322","author":"Yang","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.jacbts.2025.04.011_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113833","article-title":"Cardiovascular phenotype of mice lacking 3-mercaptopyruvate sulfurtransferase","volume":"176","author":"Peleli","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jacbts.2025.04.011_bib12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1152\/physrev.00028.2021","article-title":"Physiological roles of hydrogen sulfide in mammalian cells, tissues, and organs","volume":"103","author":"Cirino","year":"2023","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jacbts.2025.04.011_bib13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3390\/antiox10030485","article-title":"Hydrogen sulfide as a potential therapy for heart failure\u2014past, present, and future","volume":"10","author":"Lapenna","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.jacbts.2025.04.011_bib14","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1161\/HYPERTENSIONAHA.122.19456","article-title":"Roles of hydrogen sulfide in hypertension development and its complications: what, so what, now what","volume":"80","author":"Wang","year":"2023","journal-title":"Hypertension"},{"key":"10.1016\/j.jacbts.2025.04.011_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/768607","article-title":"The cardioprotective actions of hydrogen sulfide in acute myocardial infarction and heart failure","volume":"2014","author":"Polhemus","year":"2014","journal-title":"Scientifica"},{"key":"10.1016\/j.jacbts.2025.04.011_bib16","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1161\/CIRCRESAHA.114.300505","article-title":"Emergence of hydrogen sulfide as an endogenous gaseous signaling molecule in cardiovascular disease","volume":"114","author":"Polhemus","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.jacbts.2025.04.011_bib17","doi-asserted-by":"crossref","first-page":"15560","DOI":"10.1073\/pnas.0705891104","article-title":"Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function","volume":"104","author":"Elrod","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacbts.2025.04.011_bib18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1161\/CIRCRESAHA.109.199919","article-title":"Hydrogen sulfide mediates cardioprotection through Nrf2 signaling","volume":"105","author":"Calvert","year":"2009","journal-title":"Circ Res"},{"key":"10.1016\/j.jacbts.2025.04.011_bib19","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1161\/CIRCRESAHA.121.319817","article-title":"Mitochondrial H2S regulates BCAA catabolism in heart failure","volume":"131","author":"Li","year":"2022","journal-title":"Circ Res"},{"key":"10.1016\/j.jacbts.2025.04.011_bib20","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1096\/fj.06-6270fje","article-title":"Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation","volume":"20","author":"Zanardo","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.jacbts.2025.04.011_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2000464","article-title":"H2S signals through protein S-sulfhydration","volume":"2","author":"Mustafa","year":"2009","journal-title":"Sci Signal"},{"key":"10.1016\/j.jacbts.2025.04.011_bib22","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1073\/pnas.1321871111","article-title":"Hydrogen sulfide cytoprotective signaling is endothelial nitric oxide synthase-nitric oxide dependent","volume":"111","author":"King","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacbts.2025.04.011_bib23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/CIRCULATIONAHA.122.062874","article-title":"Cardiometabolic HFpEF: NASH of the heart","volume":"147","author":"Capone","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2025.04.011_bib24","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1161\/CIRCULATIONAHA.114.010637","article-title":"Phenomapping for novel classification of heart failure with preserved ejection fraction","volume":"131","author":"Shah","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2025.04.011_bib25","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jchf.2019.09.009","article-title":"Clinical phenogroups in heart failure with preserved ejection fraction","volume":"8","author":"Cohen","year":"2020","journal-title":"JACC Heart Failure"},{"key":"10.1016\/j.jacbts.2025.04.011_bib26","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/hep.32577","article-title":"Hepatocellular cystathionine gamma lyase\/hydrogen sulfide attenuates nonalcoholic fatty liver disease by activating farnesoid X receptor","volume":"76","author":"Xu","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jacbts.2025.04.011_bib27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.niox.2014.12.013","article-title":"Hydrogen sulfide attenuates high fat diet-induced cardiac dysfunction via the suppression of endoplasmic reticulum stress","volume":"46","author":"Barr","year":"2015","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.jacbts.2025.04.011_bib28","doi-asserted-by":"crossref","first-page":"13829","DOI":"10.1073\/pnas.1105121108","article-title":"Hydrogen sulfide replacement therapy protects the vascular endothelium in hyperglycemia by preserving mitochondrial function","volume":"108","author":"Suzuki","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacbts.2025.04.011_bib29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1743-7075-8-53","article-title":"Garlic improves insulin sensitivity and associated metabolic syndromes in fructose fed rats","volume":"8","author":"Padiya","year":"2011","journal-title":"Nutr Metab (Lond)"},{"key":"10.1016\/j.jacbts.2025.04.011_bib30","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1097\/00004872-200310000-00015","article-title":"The role of hydrogen sulfide generation in the pathogenesis of hypertension in rats induced by inhibition of nitric oxide synthase","volume":"21","author":"Zhong","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.jacbts.2025.04.011_bib31","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1007\/s00125-023-05973-w","article-title":"Incretins and cardiovascular disease: to the heart of type 2 diabetes?","volume":"66","author":"Solini","year":"2023","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.jacbts.2025.04.011_bib32","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacbts.2025.04.011_bib33","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacbts.2025.04.011_bib34","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacbts.2025.04.011_bib35","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Retatrutide Phase 2 Obesity Trial I. Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacbts.2025.04.011_bib36","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/S0140-6736(22)02033-5","article-title":"LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial","volume":"400","author":"Urva","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jacbts.2025.04.011_bib37","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1161\/CIRCRESAHA.122.321326","article-title":"Hydrogen sulfide modulates endothelial\u2013mesenchymal transition in heart failure","volume":"132","author":"Li","year":"2023","journal-title":"Circ Res"},{"key":"10.1016\/j.jacbts.2025.04.011_bib38","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017544","article-title":"Endothelial cell cystathionine \u03b3-lyase expression level modulates exercise capacity, vascular function, and myocardial ischemia reperfusion injury","volume":"9","author":"Xia","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacbts.2025.04.011_bib39","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.1021\/jacs.6b01373","article-title":"pH-controlled hydrogen sulfide release for myocardial ischemia-reperfusion injury","volume":"138","author":"Kang","year":"2016","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.jacbts.2025.04.011_bib40","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jacbts.2018.08.011","article-title":"Hydrogen sulfide attenuates renin angiotensin and aldosterone pathological signaling to preserve kidney function and improve exercise tolerance in heart failure","volume":"3","author":"Li","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jacbts.2025.04.011_bib41","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1161\/CIRCRESAHA.121.319817","article-title":"Mitochondrial H(2)S regulates BCAA catabolism in heart failure","volume":"131","author":"Li","year":"2022","journal-title":"Circ Res"},{"key":"10.1016\/j.jacbts.2025.04.011_bib42","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1161\/CIRCRESAHA.122.321326","article-title":"Hydrogen sulfide modulates endothelial-mesenchymal transition in heart failure","volume":"132","author":"Li","year":"2023","journal-title":"Circ Res"},{"key":"10.1016\/j.jacbts.2025.04.011_bib43","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1161\/CIRCHEARTFAILURE.113.000299","article-title":"Hydrogen sulfide attenuates cardiac dysfunction after heart failure via induction of angiogenesis","volume":"6","author":"Polhemus","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacbts.2025.04.011_bib44","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.028480","article-title":"Combination sodium nitrite and hydralazine therapy attenuates heart failure with preserved ejection fraction severity in a \u201c2-hit\u201d murine model","author":"Lapenna","year":"2023","journal-title":"Journal of the American Heart Association"},{"key":"10.1016\/j.jacbts.2025.04.011_bib45","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/sj.bjp.0706014","article-title":"Role of hydrogen sulphide in haemorrhagic shock in the rat: protective effect of inhibitors of hydrogen sulphide biosynthesis","volume":"143","author":"Mok","year":"2004","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jacbts.2025.04.011_bib46","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/nprot.2013.055","article-title":"Imaging of neutral lipids by oil red O for analyzing the metabolic status in health and disease","volume":"8","author":"Mehlem","year":"2013","journal-title":"Nat Protoc"},{"key":"10.1016\/j.jacbts.2025.04.011_bib47","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1093\/cvr\/cvac133","article-title":"Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions","volume":"118","author":"Pugliese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacbts.2025.04.011_bib48","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/bs.mie.2014.11.034","article-title":"Anti-inflammatory and cytoprotective properties of hydrogen sulfide","volume":"555","author":"Gemici","year":"2015","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.jacbts.2025.04.011_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/ars.2017.7058","article-title":"A review of hydrogen sulfide synthesis, metabolism, and measurement: is modulation of hydrogen sulfide a novel therapeutic for cancer?","volume":"31","author":"Cao","year":"2019","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.jacbts.2025.04.011_bib50","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jchf.2020.03.008","article-title":"Impaired exercise tolerance in heart failure with preserved ejection fraction: quantification of multiorgan system reserve capacity","volume":"8","author":"Nayor","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacbts.2025.04.011_bib51","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021654","article-title":"Nonalcoholic fatty liver disease and risk of heart failure among Medicare beneficiaries","volume":"10","author":"Fudim","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacbts.2025.04.011_bib52","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1161\/CIRCRESAHA.122.320257","article-title":"Heart failure with preserved ejection fraction: heterogeneous syndrome, diverse preclinical models","volume":"130","author":"Roh","year":"2022","journal-title":"Circ Res"},{"key":"10.1016\/j.jacbts.2025.04.011_bib53","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1161\/CIRCHEARTFAILURE.113.000539","article-title":"Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model","volume":"6","author":"Hamdani","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacbts.2025.04.011_bib54","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1152\/physrev.00028.2021","article-title":"Physiological roles of hydrogen sulfide in mammalian cells, tissues, and organs","volume":"103","author":"Cirino","year":"2023","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.jacbts.2025.04.011_bib55","doi-asserted-by":"crossref","first-page":"H2316","DOI":"10.1152\/ajpheart.00331.2004","article-title":"Hydrogen sulfide-induced relaxation of resistance mesenteric artery beds of rats","volume":"287","author":"Cheng","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jacbts.2025.04.011_bib56","doi-asserted-by":"crossref","first-page":"9161","DOI":"10.1073\/pnas.1202916109","article-title":"Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angiogenesis and endothelium-dependent vasorelaxation","volume":"109","author":"Coletta","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacbts.2025.04.011_bib57","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1161\/HYPERTENSIONAHA.116.08964","article-title":"Impaired hydrogen sulfide-mediated vasodilation contributes to microvascular endothelial dysfunction in hypertensive adults","volume":"69","author":"Greaney","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.jacbts.2025.04.011_bib58","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/jcmm.12077","article-title":"Crosstalk between hydrogen sulfide and nitric oxide in endothelial cells","volume":"17","author":"Altaany","year":"2013","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.jacbts.2025.04.011_bib59","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1096\/fj.15-278648","article-title":"Cystathionine beta-synthase regulates endothelial function via protein S-sulfhydration","volume":"30","author":"Saha","year":"2016","journal-title":"FASEB J"},{"key":"10.1016\/j.jacbts.2025.04.011_bib60","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1161\/CIRCULATIONAHA.118.034757","article-title":"Cystathionine gamma lyase sulfhydrates the RNA binding protein human antigen R to preserve endothelial cell function and delay atherogenesis","volume":"139","author":"Bibli","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2025.04.011_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113038","article-title":"Anti-atherogenic effect of hydrogen sulfide by over-expression of cystathionine gamma-lyase (CSE) gene","volume":"9","author":"Cheung","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jacbts.2025.04.011_bib62","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1161\/CIRCULATIONAHA.113.002208","article-title":"Decreased endogenous production of hydrogen sulfide accelerates atherosclerosis","volume":"127","author":"Mani","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2025.04.011_bib63","article-title":"Hydrogen sulfide inhibits the development of atherosclerosis with suppressing CX3CR1 and CX3CL1 expression","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jacbts.2025.04.011_bib64","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1161\/CIRCULATIONAHA.109.920991","article-title":"Genetic and pharmacologic hydrogen sulfide therapy attenuates ischemia-induced heart failure in mice","volume":"122","author":"Calvert","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2025.04.011_bib65","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.112.000855","article-title":"H(2)S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase","volume":"127","author":"Kondo","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2025.04.011_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231234","article-title":"The evolving systemic biomarker milieu in obese ZSF1 rat model of human cardiometabolic syndrome: characterization of the model and cardioprotective effect of GDF15","volume":"15","author":"Stolina","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jacbts.2025.04.011_bib67","first-page":"491","article-title":"Characterization of liver changes in ZSF1 rats, an animal model of metabolic syndrome","volume":"109","author":"Borges","year":"2017","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.jacbts.2025.04.011_bib68","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/cvr\/cvab206","article-title":"Discovery of a first-in-class inhibitor of sulfide:quinone oxidoreductase that protects against adverse cardiac remodelling and heart failure","volume":"118","author":"Jackson","year":"2022","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacbts.2025.04.011_bib69","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10741-018-9758-0","article-title":"Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials","volume":"24","author":"Kapelios","year":"2019","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jacbts.2025.04.011_bib70","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000034693","article-title":"SGLT2 inhibitors among patients with heart failure with preserved ejection fraction: A meta-analysis of randomised controlled trials","volume":"102","author":"Jaiswal","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jacbts.2025.04.011_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102782","article-title":"GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review","volume":"75","author":"Alfaris","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jacbts.2025.04.011_bib72","article-title":"Glucagon-like peptide agonists: A prospective review","volume":"7","author":"Mariam","year":"2024","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1016\/j.jacbts.2025.04.011_bib73","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jacbts.2025.04.011_bib74","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacbts.2025.04.011_bib75","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/s41591-023-02526-x","article-title":"Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial","volume":"29","author":"Borlaug","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jacbts.2025.04.011_bib76","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.jacc.2024.08.028","article-title":"Inflammation in obesity-related HFpEF: the STEP-HFpEF program","volume":"84","author":"Verma","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2025.04.011_bib77","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.jacc.2024.08.021","article-title":"Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure","volume":"84","author":"Solomon","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2025.04.011_bib78","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacbts.2025.04.011_bib79","article-title":"Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial","author":"Borlaug","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jacbts.2025.04.011_bib80","article-title":"Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy","author":"Kramer","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2025.04.011_bib81","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41574-018-0118-x","article-title":"Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases","volume":"15","author":"Clemmensen","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jacbts.2025.04.011_bib82","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","article-title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","volume":"12","author":"le Roux","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacbts.2025.04.011_bib83","doi-asserted-by":"crossref","DOI":"10.1111\/dom.16167","article-title":"Subgroup analysis by sex and baseline BMI in people with a BMI >\/=27 kg\/m(2) in the phase 2 trial of survodutide, a glucagon\/GLP-1 receptor dual agonist","author":"le Roux","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacbts.2025.04.011_bib84","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/dom.16052","article-title":"Survodutide, a glucagon receptor\/glucagon-like peptide-1 receptor dual agonist, improves blood pressure in adults with obesity: a post hoc analysis from a randomized, placebo-controlled, dose-finding, phase 2 trial","volume":"27","author":"le Roux","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacbts.2025.04.011_bib85","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00125-023-06053-9","article-title":"Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon\/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial","volume":"67","author":"Bluher","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacbts.2025.04.011_bib86","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.jchf.2024.09.004","article-title":"Survodutide for the treatment of obesity: rationale and design of the SYNCHRONIZE cardiovascular outcomes trial","volume":"12","author":"Kosiborod","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacbts.2025.04.011_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101633","article-title":"BI 456906: discovery and preclinical pharmacology of a novel GCGR\/GLP-1R dual agonist with robust anti-obesity efficacy","volume":"66","author":"Zimmermann","year":"2022","journal-title":"Mol Metab"},{"key":"10.1016\/j.jacbts.2025.04.011_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122491","article-title":"Role of hydrogen sulfide in the regulation of lipid metabolism: Implications on cardiovascular health","volume":"341","author":"Flori","year":"2024","journal-title":"Life Sci"},{"key":"10.1016\/j.jacbts.2025.04.011_bib89","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/bph.14556","article-title":"Hydrogen sulfide and hepatic lipid metabolism - a critical pairing for liver health","volume":"177","author":"Loiselle","year":"2020","journal-title":"Br J Pharmacol"}],"container-title":["JACC: Basic to Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X25001858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X25001858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T17:29:44Z","timestamp":1763659784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452302X25001858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":89,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2452302X25001858"],"URL":"https:\/\/doi.org\/10.1016\/j.jacbts.2025.04.011","relation":{},"ISSN":["2452-302X"],"issn-type":[{"value":"2452-302X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hydrogen Sulfide Deficiency and Therapeutic Targeting in Cardiometabolic HFpEF","name":"articletitle","label":"Article Title"},{"value":"JACC: Basic to Translational Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacbts.2025.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"101297"}}